LRG Staff

Home/LRG Staff

About LRG Staff

This author has not yet filled in any details.
So far LRG Staff has created 457 blog entries.

LRG Webcast Series: New Treatment Options for Advanced GIST & Concerns about the Coronavirus

During this webcast presentation, Dr. Michael Heinrich will discuss these two new treatment options for advanced GIST. Dr. Heinrich will explain how each of these drugs works to target mutations for which there has previously been no targeted treatment and discuss the current coronavirus outbreak.

By |2020-04-14T11:25:11-04:00March 24th, 2020|Drug Treatment, GIST Education, News, Webcast|

One Perspective on the BLU-285 Trial (avapritinib/Ayvakit)

LRG members Jennifer & Owen Moore give their perspective on participating in the Phase I BLU-285 trial at OSHU with Dr. Michael Heinrich. After three other drug treatment lines and faced with several growing tumors, the BLU-285 (avapritinib) trial was Owen’s best option.

By |2020-03-09T10:18:42-04:00February 28th, 2020|D842V, News, Newsletter|

Patient Advocate’s Story Unfolds in RARE Revolution Magazine

Deb Melikian, patient advocate, and Dr. Jason Sicklick, GIST expert & researcher, share the story of their unique partnership which began at an LRG GIST Day of Learning in the rare partners issue of RARE Revolution Magazine.

By |2020-02-04T08:53:11-05:00February 4th, 2020|Advocacy, News, SDH-Deficient GIST|

Breaking News for GIST Patients – Avapritinib Approved!

Blueprint Medicines announced that the FDA has approved AYVAKIT™ (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.

By |2020-01-10T16:06:14-05:00January 9th, 2020|News|